araag2/HINT huggingface dataset:
Clinical trial NCT01832766 (phase 1/phase 2, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: dronabinol
SMILES: [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1
Reason stopped: 
    unable to find subjects with schizophrenia that were using only cannabis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male and females

          -  18 and 50 years of age

          -  Diagnosis of schizophrenia

          -  Chronic cannabis users who have used for at least 1 year

          -  Using cannabis at least once weekly

          -  Currently being treated with antipsychotic medication

          -  Must be on a the same dose of antipsychotic medication for at least 3 months.

          -  Females of childbearing potential must use an adequate form of birth control while
             participating.

          -  Participants will be required to have blood pressures greater than 90/60 and less than
             140/90.

        Exclusion Criteria:

          -  Use of illicit drugs other than cannabis

          -  Any psychiatric hospitalizations within 3 months

          -  pregnancy in females

          -  taking clozapine
Clinical trial NCT00324623 (phase 1, status: completed)
Conditions: melanoma (skin)
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52
Drugs: cyclophosphamide, fludarabine phosphate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of metastatic melanoma

          -  Progressive disease after receiving prior Melan-A peptide vaccine on an immunotherapy
             protocol of the Ludwig Institute AND achieved a detectable immune response (increase
             of specific CD8^+ TET^+ Melan-A)

          -  Tumor must express MART-1/Melan-A antigen

          -  HLA-A2 positive

          -  Not eligible for other protocols due to progressive disease OR maximum number of
             vaccine injections with stable disease has been attained

        PATIENT CHARACTERISTICS:

          -  Performance status 0-2

          -  Whole blood counts normal

          -  Pulmonary status normal

          -  Transaminases < 1.5 times upper limit of normal (ULN)

          -  Gamma-glutamyl-transferase < 1.5 times ULN

          -  Bilirubin normal

          -  Creatinine clearance > 70 mL/min

          -  No major uncontrolled heart disease

          -  No arterial hypertension

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior chemotherapy, biologic therapy, radiotherapy, and/or surgery allowed
Clinical trial NCT01451632 (phase 1, status: completed)
Conditions: colorectal cancer, squamous cell head and neck cancer, non-small cell lung cancer, triple negative breast cancer, other tumors with egfr dependence
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: mm-121, irinotecan, cetuximab
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  No standard options remaining

          -  Adequate liver and kidney functions

          -  18 years of age or above

        Exclusion Criteria:

          -  History of any secondary active cancer in the last 3 years.

          -  Pregnant or breast feeding

          -  History of severe allergic reactions or contraindications to cetuximab or irinotecan
Clinical trial NCT01291914 (phase 1/phase 2, status: completed)
Conditions: osteoarthritis, knee
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: fx005, placebo 1 (carrier), placebo 2 (diluent)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥40 years of age

          -  Diagnosis of unilateral or bilateral osteoarthritis of the knee for at least 6 months;
             confirmation of osteoarthritis according to American College of Rheumatology Criteria
             (clinical and radiological)

          -  Kellgren-Lawrence grades II or III

          -  Mean score for the WOMAC A subscale (pain) between 2.0 and 3.5 for the index knee

          -  Score of 2-3 for the WOMAC A1 score (pain on walking) for the index knee

          -  Body mass index ≤ 40 kg/m2

          -  Willingness to abstain from use of restricted medications during the study

          -  Willingness and ability to comply with the study procedures and visit schedule

        Exclusion Criteria:

          -  Kellgren-Lawrence Grade 0, I or IV radiographic stage of the index knee

          -  Clinically apparent tense effusion in index knee

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Clinical signs and symptoms of active knee infection or crystal disease

          -  Intra-articular corticosteroid within 3 months of Screening

          -  Intra-articular hyaluronic acid within 6 months of Screening

          -  Other intra-articular therapy within 3 months of Screening

          -  Prior arthroscopic or open surgery of the index knee within 12 months of Screening

          -  Planned/anticipated surgery of the index knee during the study period

          -  History of malignancy or other serious, non-malignant, significant, acute or chronic
             medical (e.g.. uncontrolled diabetes) or active psychiatric illness

          -  Skin breakdown at the knee where the injection would take place

          -  Women who are pregnant, nursing or likely to become pregnant during the time of the
             study

          -  Women of child-bearing potential (not surgically sterile or post-menopausal for at
             least 1 year) not using effective contraception
Clinical trial NCT00565227 (phase 1, status: terminated)
Conditions: non-small-cell lung carcinoma, prostate cancer, bladder cancer, urothelial carcinoma
ICD codes: D02.20, D02.21, D02.22, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: vorinostat (suberoylanilide hydroxamic acid), docetaxel
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    closed due to toxicity
  
Eligibility criteria:

        Inclusion Criteria:

          1. There is no limit on prior courses of chemotherapy as long as the regimen did not
             contain docetaxel. Prior use of paclitaxel (Taxol) or other taxanes is permissible.

          2. Only patients with non-small cell lung, prostate, and bladder/urothelial cancer that
             has progressed after chemotherapy or after hormone therapy.

        Exclusion Criteria:

          1. Patients who have had chemotherapy or radiotherapy within 3 weeks.

          2. Patients may not be receiving any other investigational agents nor had prior treatment
             with histone deacetylase (HDAC) inhibitors (i.e. Valproic acid, PXD-001, Depsipeptide,
             MS-275 and LAQ-824)

          3. Significant cardiovascular disease including congestive heart failure
Clinical trial NCT00551122 (phase 1/phase 2, status: unknown status)
Conditions: brain and central nervous system tumors, extragonadal germ cell tumor, ovarian cancer, testicular germ cell tumor
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, E29.0, E29.1, E29.8, E29.9, E89.5, N50.811, N50.812
Drugs: cisplatin, gemcitabine hydrochloride, ifosfamide, paclitaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Meets the following criteria:

               -  Histologically confirmed extracranial primary germ cell cancer, seminoma, or
                  nonseminoma

                    -  Unresectable metastatic disease

                    -  No completely resected cancer

               -  Rising serum markers (i.e., alpha-fetoprotein and human chorionic gonadotropin)
                  on sequential measurement or biopsy-proven unresectable germ cell cancer

          -  In first relapse after a single prior cisplatin-containing combination chemotherapy

               -  Patients with late relapse (i.e., > 2 years post initial chemotherapy) should be
                  considered for surgery rather than chemotherapy, if technically feasible

          -  No patients with cerebral metastases alone

               -  Progressive cerebral and systemic disease may be considered for this study,
                  provided cranial irradiation is also considered as a component of care

        PATIENT CHARACTERISTICS:

          -  Medically and psychologically fit to receive this intensive chemotherapy schedule

          -  WBC > 3.5 times 10^9/L

          -  Platelet count > 130 times 10^9/L

          -  Glomerular filtration rate ≥ 50 mL/min (as determined by 24 hour creatinine clearance
             or nuclear medicine technique)

          -  Fertile patients must use effective contraception

          -  No other prior malignancy except successfully treated nonmelanoma skin cancer or
             superficial bladder cancer

          -  No prior allergic reactions to cisplatin or other platinum compounds

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
Clinical trial NCT00621725 (phase 1, status: completed)
Conditions: advanced cancer, hepatic impairment
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123, Z73.82, G31.84, M10.38, M10.30, M10.311, M10.312, M10.319
Drugs: azd2171
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Advanced solid tumour (not prostate cancer) for which no standard therapy exists

          -  WHO performance status 0-2

          -  Bilirubin levels within the target range

        Exclusion Criteria:

          -  Unstable brain/meningeal metastases

          -  Inadequate bone marrow reserve

          -  Biochemistry/haematology results outside of required ranges

          -  History of significant GI impairment
Clinical trial NCT01942382 (phase 1, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:- Participants had to have the capability to provide informed consent in
        writing to participate in the study

          -  Participants with a diagnosis of schizophrenia in accordance with the diagnostic
             criteria for Diagnostic and Statistical Manual of Mental Disorders -IV-TR (DSM-IV-TR)

          -  Participants whose psychiatric symptom is considered stable by the
             investigator/subinvestigator at the time of giving informed consent

          -  Participants with a Positive and Negative Syndrome Scale (PANSS) score of less than or
             equal to 4 (moderate) in the following 9 items at screening: delusion, conceptual
             disorganization, hallucinatory behavior, excitement, grandiosity,
             suspiciousness/persecution, hostility, uncooperativeness, poor impulse control

          -  Participants with an experience of taking a risperidone formulation or a paliperidone
             formulation by 8 days before the initial day (Day 1) of the study treatment

        Exclusion Criteria:- DSM-IV-TR diagnosis other than schizophrenia

          -  DSM-IV-TR diagnosis of substance-related disorders within 180 days before the date of
             screening

          -  At a risk of suicide or other-injurious behavior as considered by the
             investigator/subinvestigator , and participants with a history of suicide attempts

          -  Concurrent condition of Parkinson's disease (except for drug-induced extrapyramidal
             syndrome) - Concurrent condition or history of symptomatic cerebrovascular accident
Clinical trial NCT00374985 (phase 1/phase 2, status: completed)
Conditions: esophageal neoplasms, stomach neoplasms
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10, D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5
Drugs: docetaxel, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adenocarcinoma of gastric-esophagal junction

          -  stage II to III

          -  unidimensional measurable disease

        Exclusion Criteria:

          -  surgery of primary tumor

          -  metastasis

          -  prior chemo- or radiotherapy
Clinical trial NCT00350844 (phase 1/phase 2, status: terminated)
Conditions: sickle cell disease, pulmonary hypertension
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218, I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: hydroxyurea
SMILES: NC(=O)NO
Reason stopped: 
    low subject accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age between 10 and 25 years old

          -  Sickle cell disease with hemoglobin SS, SC or S-B^0 thalassemia confirmed on
             hemoglobin electrophoresis

          -  Tricuspid regurgitant jet velocity (TRJV) equal to or greater than 2.5 m/sec on 2
             baseline Doppler echocardiograms at least 3 months apart

        Exclusion Criteria:

          -  Patients already being treated with hydroxyurea

          -  Patients on a chronic transfusion protocol

          -  Patients with evidence of hepatic (alanine aminotransferase [ALT] equal to or greater
             than 2 SD above normal) or renal dysfunction (creatinine [Cr] equal to or greater than
             2 SD above normal)

          -  Patients who are pregnant

          -  Patients with documented causes of severe pulmonary hypertension other than from SCD
Clinical trial NCT01682902 (phase 1, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: faster-acting insulin aspart, faster-acting insulin aspart, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes mellitus (diagnosed clinically) for at least 12 months prior to the
             screening visit (Visit 1)

          -  Treatment with the same insulin analogue by CSII (continuous subcutaneous insulin
             infusion) for the previous 3 months prior to the screening visit (Visit 1)

          -  Using a MiniMed Paradigm® pump (515/715, 522/722 or 523/723) for the previous 6 months
             prior to the screening visit (Visit 1)

          -  Glycosylated haemoglobin (HbA1c) below or equal to 9.0% by central laboratory

          -  Body Mass Index (BMI) below or equal to 35.0 kg/m^2

        Exclusion Criteria:

          -  History of diabetic ketoacidsosis (DKA) episodes requiring hospitalization within 6
             months prior to the screening visit (Visit 1)

          -  History of abscess at the infusion site within 6 months prior to the screening visit
             (Visit 1)

          -  Hypoglycaemic unawareness as judged by the Investigator or history of severe
             hypoglycaemic episodes requiring hospitalization within the last 6 months prior to the
             screening visit (Visit 1)
Clinical trial NCT01154387 (phase 1/phase 2, status: unknown status)
Conditions: end stage renal disease, renal transplant
ICD codes: N18.6, I12.0, I13.11, I13.2, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: anti-thymocyte globulin, tol101, tol101, steroids, tacrolimus, mycophenolate mofetil (mmf)
SMILES: COC1=CC=CC=C1OCC(O)CO, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, COC(=O)\C=C\C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Recipient of a primary renal transplant from a living or standard criteria cadaveric
             donor

          -  Male or female 18-60 years of age

          -  Recipient with a PRA < 20%

        Exclusion Criteria:

          -  Previous solid organ transplant

          -  Recipient of HLA-identical kidney allograft transplant

          -  Recipient of an ABO incompatible donor kidney

          -  Known HIV infection or other major infection

          -  History of malignancy within 3 years (excluding treated basal cell or squamous cell
             carcinoma of the skin) prior to enrollment

          -  History of tuberculosis

          -  Recipient with cardiovascular disease

          -  Treatment with immunosuppressive medications within 1 month prior to enrollment

          -  Known or suspected allergy to mice

          -  Pregnant or lactating

          -  Unable or unwilling to participate in all required study activities for the duration
             of the study (6 months)
Clinical trial NCT00450138 (phase 1, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: zd6474 (vandetanib), cisplatin
SMILES: COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Stage III-IV squamous cell carcinoma of the head and neck

        Exclusion Criteria:

          -  No previous treatment for head and neck cancer, adequate cardiac function
Clinical trial NCT01340066 (phase 1/phase 2, status: completed)
Conditions: urinary incontinence
ICD codes: N39.492, R32, R39.81, N39.498, L24.A2
Drugs: uish001, matching placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Women who have moderate to severe urge, stress or mixed Urinary Incontinence

        Exclusion Criteria:

          -  Medical history of migraines, neurologic problems, swallowing disorder, stroke or
             severe depression.

          -  Medical history of heart failure, peripheral edema or moderate to severe asthma or
             chronic obstructive pulmonary disease (COPD)

          -  Certain restricted medications

          -  Any other condition that would interfere with the safety of the subject
Clinical trial NCT00306202 (phase 1, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: dasatinib, dasatinib, dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Ph-positive (Ph+) Chronic Myelogenous Leukemia in chronic, accelerated or blast phase
             or Ph+ acute lymphoblastic leukemia (ALL) with imatinib-resistant disease or
             intolerance to imatinib.

          -  Ph-negative acute leukemia in second or subsequent relapse

          -  Age >1 and <21 years

          -  Lansky or Karnofsky scale >60

          -  Life expectancy >3 weeks

          -  Adequate hepatic and renal function

          -  Written informed consent

        Exclusion Criteria:

          -  Subjects for whom potentially-curative therapy was available, including electing
             immediate [ie, planned <45 days] stem-cell transplantation. Subjects in Stratum 1 were
             to have had an ongoing identical HLA donor search, and may have discontinued study if
             a donor became available.)

          -  Subjects with symptomatic central nervous system (CNS) disease (eg, convulsions due to
             their CNS disease).

          -  Subjects who had not recovered from acute toxicity of previous therapy.

          -  Clinically-significant disorder of platelet function (eg, von Willebrand's disease) or
             ongoing gastrointestinal bleeding.

          -  Serious uncontrolled medical disorder or active infection

          -  Uncontrolled or significant cardiovascular disease

          -  Use of any investigational agent or any other anticancer agent within 14 days prior to
             treatment start.

          -  Prior therapy with dasatinib

          -  Subjects taking medications that irreversibly inhibit platelet function or
             anticoagulants.

          -  Subjects taking certain medications that are accepted to have a risk of causing QTc
             prolongation.

          -  Women of Child Bearing Potential with a positive pregnancy test prior to study drug
             administration.

          -  Expected noncompliance, or unable to have regular follow-up due to psychologic,
             social, familial, or geographic reasons.

          -  Subjects who are compulsorily detained for legal reasons or treatment of either a
             psychiatric or physical (eg, infectious disease) illness must not be enrolled into
             this study.